medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (4)


Racial Disparities in Hepatitis C Treatment Eligibility

Sims OT, Pollio DE, Hong BA, North CS

Idioma: Ingles.
Referencias bibliográficas: 37
Paginas: 530-537
Archivo PDF: 144.74 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.

  3. Liu G, Holmberg SD, Kamili S, Xu F. Racial disparities in the proportion of current, unresolved hepatitis C virus infections in the United States, 2003-2010. Dig Dis Sci 2014; 59: 1950- 7. doi:10.1007/s10620-014-3059-9.

  4. Mir HM, Stepanova M, Afendy M, Kugelmas M, Younossi ZM. African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol 2012; 46:e62-5. doi:10.1097/ MCG.0b013e318238352b.

  5. Bailey RK, Muir AJ, Howell CD, Bright C, Roane PR, Teshale E, Johnson CM, et al. The hepatitis C crisis in the African American Community: findings and recommendations. J Natl Med Assoc 2013; 105: 108-11.

  6. Tohme RA, Xing J, Liao Y, Holmberg SD. Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010. Am J Public Health 2013; 103: 112-9. doi:10.2105/AJPH.2012.300858.

  7. Trooskin SB, Navarro VJ, Winn RJ, Axelrod DJ, McNeal AS, Velez M, Herrine SK, et al. Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenterol 2007; 13: 1074-8.

  8. Hare CB, Morris JA, Chu A, Gotz V, Loveland JJ, Hodes D, Klaskala W. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. Pharmacoepidemiol Drug Saf 2006; 15: 71-6. doi:10.1002/pds.1146.

  9. Rousseau CM, Ioannou GN, Todd-Stenberg JA, Sloan KL, Larson MF, Forsberg CW, Dominitz JA. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am J Public Health 2008; 98: 846-852. doi:10.2105/AJPH.2007.113225.

  10. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-389. doi:10.1136/ gut.2006.099150.

  11. Jin R, Cai L, Tan M, McHutchison JG, Dowling TC, Howell CD. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. Am J Gastroenterol 2012; 107: 1675-83. doi:10.1038/ajg.2012.306.

  12. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley- Lucas TE, Afdhal N, Brown RS, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7. doi:10.1053/j.gastro.2006.06.008.

  13. Flamm SL, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowei NH, Sullivan JC, et al. Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity. J Clin Gastroenterol 2015; 49: 336-44.

  14. Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, Marbury TC, et al. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther 2012; 35: 1209-20. doi:10.1111/ j.1365-2036.2012.05079.x.

  15. Meng Q, Rani MRS, Sugalski JM, Judge CJ, Phat S, Rodriguez B, Blanton RE, et al. Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ ribavirin therapy in chronic H. J Infect Dis 2014; 209: 1591-601. doi:10.1093/infdis/jit677.

  16. Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012; 36: 104-114. doi:10.1111/ j.1365-2036.2012.05145.x.

  17. Donlin MJ, Cannon NA, Aurora R, Wahed AS, Di Bisceglie AM, Tavis JE, Virahep-C Study Group, et al. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 2010; 5: e9032. doi:10.1371/journal.pone.0009032.

  18. Schaeffer S, Khalili M. Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics. Ann Hepatol 2015; 14: 234-42.

  19. Smith BD, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965. Ann Intern Med 2013; 158: 705. doi:10.7326/0003-4819-158-9-201305070-00016.

  20. Burton MJ, Passarella MJ, McGuire BM. Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers. South Med J 2012; 105: 431-6. doi:10.1097/SMJ.0b013e 31825f033e.

  21. Rivers D, August EM, Sehovic I, Lee Green B, Quinn GP. A systematic review of the factors influencing African Americans' participation in cancer clinical trials. Contemp Clin Trials 2013; 35: 13-32. doi:10.1016/j.cct.2013.03.007.

  22. Penberthy L, Brown R, Wilson-Genderson M, Dahman B, Ginder G, Siminoff LA. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials 2012; 9: 788-797. doi:10.1177/ 1740774512458992.

  23. Advani AS, Atkeson B, Brown CL, Peterson BL, Fish L, Johnson JL, Gockerman JP, et al. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer 2003; 97: 1499-1506. doi:10.1002/ cncr.11213.

  24. Durant RW, Wenzel JA, Scarinci IC, Paterniti DA, Fouad MN, Hurd TC, Martin MY. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer 2014; 120(Suppl): 1097-105. doi:10.1002/ cncr.28574.

  25. North CS, Sims O, Hong BA, Jain MK, Brown G, Lisker-Melman M, Pollio DE. An empirical study of alcohol consumption by patients considering HCV treatment. Am J Drug Alcohol Abuse 2014; 40: 484-9. doi:10.3109/00952990.2014.945592.

  26. Robins LN, Cottler LB, Compton WM, Bucholz K, North CS, Rourke KM. Diagnostic Interview Schedule for the DSM-IV (DIS-IV). St Louis: Washington University; 2000.

  27. World Health Organization. The Composite International Diagnostic Interview-Substance Abuse Module. Geneva, Switzerland. 2004. Available from: http://www.hcp.med.harvard.edu/ wmhcidi/about.php.

  28. Schilling RF, Bidassie B, El-Bassel N. Detecting cocaine and opiates in urine: comparing three commercial assays. J Psychoactive Drugs 1999; 31: 305-13. doi:10.1080/ 02791072.1999.10471761.

  29. Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, et al. Racial differences in hepatitis C treatment eligibility. Hepatology 2011; 54: 70-8. doi:10.1002/ hep.24358.

  30. Hung C-H, Wang J-H, Hu T-H, Chen CH, Chang KC, Yen YH, Kuo YH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16: 2265-71.

  31. Hsu Y-C, Lin J-T, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-302. doi:10.1002/hep.26892.

  32. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. 2016. h t t p ://hcvguidelines.org/sites/default/files/HCV-Guidance_July_2016_b.pdf. Accessed September 15, 2016.

  33. Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 2006; 55: 585.

  34. Chu CJ, Lee SD, Hung TH, Lin HC, Hwang SJ, Lee FY, Lu RH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon α-2b plus ribavirin. Aliment Pharmacol Ther 2009; 29: 46-54. doi:10.1111/j.1365- 2036.2008.03823.x.

  35. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.

  36. Doyle M-A, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCVHIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials 2016; 17: 331. doi:10.1186/s13063-016-1454-6.

  37. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatmentnaive patients infected with HCV genotype 1. Gut 2012; 61: 1473-80. doi:10.1136/gutjnl-2011-300749; 10.1136/gutjnl- 2011-300749.




2020     |     www.medigraphic.com